Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Warfarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 known ✓ | Q9BQB6 | 3/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.97 |
| ▸ | ALB | P02768 | 2/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | BRD4 | O60885 | 1/20 | 0.67 |
| ▸ | NQO1 | P15559 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Warfarin SCHEMBL28534047 | 1.00 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL34347 | 1.00 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL8332637 | 1.00 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL13278154 | 1.00 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL29400364 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL3689 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL662875 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL4439794 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL2139452 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL3792087 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9821039-B2 | Albumin fusion proteins | ALBUMEDIX A/S (DK) | 2017-11-21 | — | — | US | disclosed |
| US-20120252732-A1 | ALBUMIN FUSION PROTEINS | NOVOZYMES BIOPHARMA DK A/S | 2012-10-04 | — | — | US | disclosed |
| US-20120141415-A1 | Albumin Fusion Proteins | DELTA BIOTECHNOLOGY LIMITED | 2012-06-07 | — | — | US | disclosed |
| US-20120141449-A1 | Albumin Fusion Proteins | DELTA BIOTECHNOLOGY LIMITED | 2012-06-07 | — | — | US | disclosed |
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141449-A1 | Albumin Fusion Proteins | ALB, FABP1, HDGF | VKORC1 4854/4885CYP2C9 4611/4885ALB 1/4885 |
| US-20120141415-A1 | Albumin Fusion Proteins | ALB, FABP1, HDGF | VKORC1 4854/4885CYP2C9 4611/4885ALB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.